

117TH CONGRESS
2D SESSION

H. R. 1193

IN THE SENATE OF THE UNITED STATES

DECEMBER 9, 2021

Received

MAY 25, 2022

Read twice and referred to the Committee on Health, Education, Labor, and
Pensions

AN ACT

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Cardiovascular Ad-
5 vances in Research and Opportunities Legacy Act”.

6 **SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE-**

7 **SEARCH.**

8 Subpart 2 of part C of title IV of the Public Health
9 Service Act (42 U.S.C. 285b et seq.) is amended by insert-
10 ing after section 424C (42 U.S.C. 285b–7c) the following:

11 **“SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE-**

12 **SEARCH.**

13 “(a) IN GENERAL.—The Director of the National In-
14 stitutes of Health, in consultation with the Director of the
15 Institute, shall support or conduct research regarding val-
16 vular heart disease.

17 “(b) SUPPORT GUIDELINES.—The distribution of
18 funding authorized under subsection (a) may be used to
19 pursue the following outcomes:

20 “(1) Using precision medicine and advanced
21 technological imaging to generate data on individ-
22 uals with valvular heart disease.

23 “(2) Identifying and developing a cohort of in-
24 dividuals with valvular heart disease and available
25 data.

1 “(3) Corroborating data generated through clin-
2 ical trials to develop a prediction model to distin-
3 guish individuals at high risk for sudden cardiac ar-
4 rest or sudden cardiac death from valvular heart dis-
5 ease.

“(4) For other outcomes needed to acquire necessary data on valvular heart disease.

8 “(c) MITRAL VALVE PROLAPSE WORKSHOP.—Not
9 later than one year after the date of the enactment of this
10 section, the Director of the Institute shall convene a work-
11 shop composed of subject matter experts and stakeholders
12 to identify research needs and opportunities to develop
13 prescriptive guidelines for treatment of individuals with
14 mitral valve prolapse.

15 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the
16 purpose of carrying out this section, there is authorized
17 to be appropriated \$20,000,000 for each of fiscal years
18 2022 through 2026.”.

19 SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL
20 AND PREVENTION.

21 Part B of title III of the Public Health Service Act
22 (42 U.S.C. 243 et seq.) is amended by inserting after sec-
23 tion 312 the following section:

1 **“SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A**
2 **RESULT OF VALVULAR HEART DISEASE.**

3 “(a) IN GENERAL.—The Secretary, acting through
4 the Director of the Centers for Disease Control and Pre-
5 vention, may carry out projects to increase education,
6 awareness, or diagnosis of valvular heart disease and to
7 reduce the incidence of sudden cardiac death caused by
8 valvular heart disease. Such projects may be carried out
9 by the Secretary directly or through awards of grants or
10 contracts to public or nonprofit private entities. The Sec-
11 retary may directly (or through such awards) provide tech-
12 nical assistance with respect to the planning, development,
13 and operation of such projects.

14 “(b) CERTAIN ACTIVITIES.—Upon availability of ap-
15 plicable data, projects carried out under subsection (a)
16 may include—

17 “(1) continuing the activities at the Division for
18 Heart Disease and Stroke Prevention, including
19 those related to valvular heart disease;

20 “(2) broadening the awareness of the public
21 concerning the risk factors for, the symptoms of,
22 and the public health consequences of valvular heart
23 disease; and

24 “(3) enhancing surveillance of out-of-hospital
25 cardiac arrests to improve patient outcomes.

“(c) GRANT PRIORITIZATION.—The Secretary may, in awarding grants or entering into contracts pursuant to subsection (a), give priority to entities seeking to carry out projects that target populations most impacted by vascular heart disease.

6 “(d) COORDINATION OF ACTIVITIES.—The Secretary
7 shall ensure that activities under this section are coordi-
8 nated, as appropriate, with other agencies of the Public
9 Health Service that carry out activities regarding valvular
10 heart disease.

11 "(e) BEST PRACTICES.—The Secretary, acting
12 through the Director of the Centers for Disease Control
13 and Prevention, shall—

14 “(1) collect and analyze the findings of research
15 conducted with respect to valvular heart disease; and

16 “(2) taking into account such findings, publish
17 on the website of the Centers for Disease Control
18 and Prevention best practices for physicians and
19 other health care providers who provide care to indi-
20 viduals with valvular heart disease.”

Passed the House of Representatives December 8,
2021.

Attest: CHERYL L. JOHNSON,
Clerk.